Zymeworks

The U.S. approval of the cancer drug Ziihera triggers a contractual one-time payment of $0.25 billion to Zymeworks. H.C. Wainwright raised the price target from $51 to $55 and reaffirmed the buy recommendation. Zymeworks' business model combines in-house research with strategic partners and benefits from oncology growth trends. » Más en finanzen.net

Zymeworks shares climbed in premarket trading as the FDA decision on the PDUFA date of August 25, 2026, for zanidatamab (Ziihera) for HER2-positive gastric and gastroesophageal adenocarcinoma is awaited. Approval would immediately trigger a U.S. milestone payment of $250 million and could enable further global payments of up to $190 million. Analysts backed their assessments and raised price targets ahead of the date, and the planned acquisition of Theravance Biopharma is expected to strengthen the portfolio and cash flows with YUPELRI. The share price rise comes despite a weak overall market and a difficult biotech environment; the stock is trading at its highest level in more than a year. » Más en de.investing.com

Zymeworks has entered a collaboration with Gandeeva Therapeutics to generate cryo‑electron microscopy structural data to aid discovery of antibody therapeutics. The partnership focuses on high‑resolution visualization of antibody‑antigen interfaces, in particular epitope mapping on small, flexible antigens. Gandeeva has already demonstrated a structure determination at 2.6 Å resolution that is intended to support selection and optimization of antibody lead candidates. In response, Zymeworks shares rose sharply in pre‑market trading. » Más en de.investing.com